The landscape of otolaryngology is undergoing a profound transformation, marked by a shift towards less invasive procedures, the integration of cutting-edge technologies like artificial intelligence (AI) and genetic medicine, and a growing emphasis on personalized treatment strategies. These advancements, while promising, are intrinsically linked to the collaborative efforts between medical professionals and the industrial sector. ENTtoday spoke with seven leading practitioners who have successfully navigated the often-complex, yet ultimately rewarding, journey of bringing innovative ideas from the conceptual stage to widespread clinical application. Their experiences highlight the critical role of physician-industry partnerships in shaping the future of ear, nose, and throat care.

The Strategic Imperative of Physician-Industry Partnerships in ENT

Otolaryngology, a specialty characterized by its intricate anatomical confines and the need for precision, is uniquely poised for robust physician-industry collaborations. Rohan R. Walvekar, MD, Professor of Clinical Otolaryngology and Vice Chair for Head and Neck Oncology Services at Louisiana State University New Orleans School of Medicine, emphasizes this point, stating, "ENT is a procedure-heavy specialty, so we interact a lot with medical device industries—on the education and training front, as well as in innovation." He further elaborates on the inherent challenges and opportunities within the field: "We work in a very narrow, limited space, where there are anatomical constraints. We’re constantly in a state of evolution to figure out how to navigate our surgical limitations."

Dr. Walvekar’s own journey exemplifies this synergy. His initial involvement with industry began during his residency with Hood Laboratories, a company that had developed the Schaitkin Salivary Duct Cannula. Building upon this foundation, he identified a specific clinical need: the existing stent’s flange was effective for submandibular glands but less so for the parotid gland. This observation led to the development of the Walvekar Salivary Duct Stent, a testament to how direct clinical experience can inform product design. Hood Laboratories, now part of Everis Medical, continues to market the stent, demonstrating the long-term impact of such collaborations. Beyond devices, Dr. Walvekar has also leveraged technology to enhance healthcare operations, developing nDORSE, an employee recognition application that served thousands of healthcare professionals, underscoring his commitment to using technological solutions to optimize healthcare workflows.

Bringing the Physician’s Perspective to Product Development

Inna A. Husain, MD, Medical Director of Laryngology at Powers Health in Munster, Indiana, and a prominent voice in the discussion of laryngopharyngeal reflux (LPR), highlights the power of physicians to shape product development. Dr. Husain, who has cultivated a significant online presence with over 300,000 social media followers discussing LPR, notes, "My first collaboration with industry came as a referral from my local rep, who felt that her company needed to do outreach. She had become aware of me through my social media work." This initial engagement underscores how physicians can proactively position themselves as valuable partners.

Dr. Husain’s role as Vice President of Education for RefluxRaft, an alginate-based supplement developed by otolaryngologists, exemplifies the direct impact of physician input. She stresses the importance of physicians communicating the nuanced challenges of their practice to product developers: "We know the struggles in our field—the difficulties that aren’t obvious unless you are in our role." Furthermore, she emphasizes the need for diverse physician voices to ensure that developed technologies cater to a broad patient population, reflecting the heterogeneity of otolaryngological needs and opinions. This inclusive approach ensures that innovations are not only technically sound but also clinically relevant and equitable.

From Clinical Quandary to Commercial Enterprise

Sujana S. Chandrasekhar, MD, a partner at ENT and Allergy Associates in New York City, and founder, CEO, and CMO of KivviMed, offers a compelling narrative of transforming a clinical problem into a thriving biomedical company. Her entrepreneurial venture began with an serendipitous encounter with researcher Alan Mautone, whose work on pulmonary physiology led to the development of a spray that could open tubes. Dr. Chandrasekhar recognized the immediate application for her own clinical challenges, likening their collaboration to a "Reese’s collaboration."

This partnership culminated in the formation of KivviMed, whose initial product, ET CLEAR, is a targeted metered-dose inhaler designed to deliver synthetic surfactant to the Eustachian tube, thereby alleviating pain associated with Eustachian tube dilator dysfunction. The development and FDA trial process for ET CLEAR involves collaboration with Michael Hoffer, MD, at the University of Miami, illustrating the interconnectedness of clinical research and product realization.

Dr. Chandrasekhar candidly discusses the demanding nature of company building, contrasting it with the immediate gratification of surgical practice. "As a surgeon, I am used to evaluating data, forming a decision, and carrying it out, all before dinner, BAM! Company building is fits and starts, steps forward and back, and repeating your ‘pitch’ ad infinitum," she admits. Her experience underscores the need for resilience and adaptability in the entrepreneurial space. She also points to the critical importance of physician involvement from the inception of product development, citing an instance where her feedback on the ergonomic design of a balloon for surgeons of varying hand sizes led to a more user-friendly and safer device. This highlights how practical clinical feedback can directly enhance product usability and patient safety.

Innovations Driven by Patient-Centric Problem Solving

Michael J. Rutter, MD, a pediatric otolaryngologist at Cincinnati Children’s Hospital Medical Center, exemplifies the principle that significant innovations often stem from addressing the specific needs of individual patients. His work has led to the development of the Rutter Supra-Stomal Stent and the Aeris Balloon Dilation Catheter, the latter co-developed with Bryan Medical. The impetus for the balloon catheter arose from a near-catastrophic event where a previous balloon slipped during a procedure, causing a bronchial rupture. "A patient was the reason I invented the balloon," Dr. Rutter states, emphasizing the direct link between patient safety concerns and product innovation.

Dr. Rutter also contextualizes innovation within the historical evolution of pediatric otolaryngology, noting that the subspecialty itself was born from a collaboration between a physicist, an instrument maker, and an ENT physician, which led to the development of the Hopkins rod endoscope. This historical precedent underscores the enduring value of interdisciplinary collaboration in advancing the field. He offers pragmatic advice on navigating industry partnerships, cautioning against companies that develop ideas without clinical input and highlighting the potential pitfalls of advisory boards that may offer biased feedback. Dr. Rutter’s approach emphasizes rigorous evaluation, encouraging physicians to be prepared to critically assess ideas, even those presented by industry partners. His own collaborations are characterized by a focus on improving instruments and advising on the feasibility and potential risks of new products, making the process "very intellectually stimulating."

Advancing Aesthetic Injectables Through Rigorous Clinical Trials

Theda C. Kontis, MD, a facial plastic and reconstructive surgeon at the Aesthetic Center at Woodholme and Associate Professor at Johns Hopkins Medical Institutions, is a leading authority on cosmetic injectables. Her extensive involvement in over 15 multi-center clinical trials for aesthetic injectables, botulinum toxins, and dermal fillers underscores her commitment to advancing the field through evidence-based research. Dr. Kontis is currently engaged in three ongoing trials focused on neurotoxins and fillers, reflecting the dynamic nature of this area within otolaryngology.

Historically, the development of injectables was primarily the domain of dermatologists, but Dr. Kontis observes a growing participation of facial plastic surgeons in clinical trials. She acknowledges the initial hurdles in engaging with industry, which include establishing a presence and demonstrating access to a sufficient patient pool meeting trial criteria. However, she finds the process of working with industry on clinical trials highly rewarding, stating, "It’s fun to watch the development of new products. I feel that I am at the forefront of research." Her keen observation during a neurotoxin trial, where she noted the long-term improvement of glabellar lines after prolonged brow immobility, led to a published paper with Dr. Richard Glogau, illustrating how physician insights can uncover novel therapeutic benefits and drive further research.

Integrating Sleep Apnea Innovations into Clinical Practice

Maria V. Suurna, MD, Professor of Clinical Otolaryngology and Director of Sleep Surgery at the University of Miami Health System, addresses the critical need for advanced treatment options for patients with obstructive sleep apnea (OSA) who are intolerant to continuous positive airway pressure (CPAP) or traditional surgical interventions. The commercialization and FDA approval of hypoglossal nerve stimulators for OSA in 2014, spearheaded by Inspire Medical Systems, marked a significant advancement. Dr. Suurna’s career in sleep surgery coincided with Inspire’s clinical trials, leading her to become the first surgeon in New York City to utilize their upper airway stimulation system.

Her collaboration with Inspire extended beyond surgical technique to encompass patient care pathways and post-surgical management, providing her with invaluable insight into the comprehensive process of bringing an innovative treatment from clinical trial to market approval and widespread insurance coverage. This foundational experience instilled in her a deep appreciation for the intricacies involved in delivering novel therapies. Subsequently, Dr. Suurna has consulted with various companies developing OSA treatments, offering a physician’s perspective on the practicalities of clinical application, patient compliance, tolerance, and lifestyle integration—factors that engineers may not always consider. Her focus remains steadfast on optimizing patient care through thoughtful product development.

Leveraging Artificial Intelligence to Streamline Referrals

Nicole Jiam, MD, Executive Director of the UCSF Otolaryngology Innovation Center and Assistant Professor at UCSF, identified a critical bottleneck in patient access: lengthy wait times for specialist appointments and incomplete patient workups upon arrival. This frustration served as the impetus for her entrepreneurial endeavors. "Like most founders, I started with a daily and massively frustrating problem in clinic: patients waiting months for an appointment with me when they should have seen someone else entirely, and patients driving hours only to arrive presenting an incomplete workup," she explains.

Dr. Jiam’s solution, IIAM Health software, utilizes AI to empower front-line staff with clinical judgment capabilities, ensuring that patients are directed to the appropriate clinician and are adequately prepared for their appointments. This initiative aims to "uplevel everyone in the chain, rather than have the patient absorb the cost of the gap," thereby optimizing the patient journey and enhancing healthcare efficiency. She advocates for the increased involvement of practicing surgeon-entrepreneurs, emphasizing that innovations often emerge at the intersection of disciplines. Dr. Jiam’s experience highlights the transformative potential of placing the design of solutions in the hands of those closest to the problems they address, thereby enhancing the delivery of care at scale.

Expert Perspectives on Physician-Industry Collaboration

Q: Are ENTs getting involved with industry early enough?

Dr. Jiam: Frequently enough, mostly. Early enough, no. Surgeons are typically brought in at validation and at launch, once the product is essentially frozen and the expensive decisions have already been made. So, what companies are really asking for is endorsement.

Dr. Husain: ENT surgeons need to participate more in innovation and technology development from the beginning. Although I caution trainees from these early collaborations, I encourage early-career surgeons to get involved. Some technologies take years to develop. By starting early, you can be involved for multiple stages and see the product grow.

ENT Surgeons Working with Industry - ENTtoday

Dr. Walvekar: As things stand, residents and fellows don’t execute on their plans until they graduate because there are a lot of institutional regulations that tie them down, such as locking of intellectual property. We need a better pathway for them to express their ideas.

Dr. Chandrasekhar: This is a great opportunity for us old guys and gals to mentor trainees and early-career surgeons. If there is no issue with a nondisclosure agreement, when we get an opportunity to bring along a younger person, we should. This is also a chance for us to level the playing field by bringing along younger ENTs hailing from different backgrounds.

Q: When seeking to work with industry, what are the differences between working for a health organization or university versus private practice?

Dr. Rutter: As an employee of a hospital or hospital system, you are likely subject to a contract stipulating that if you have an idea, it is the property of your employer organization. If the idea flies, you get a percentage of the royalties. If you have an idea and your hospital doesn’t run with it, the polite thing would be to give it back to you—in which case it’s all on your ticket. If you speak to industry about your idea without the organization being aware, you risk getting into a lot of trouble.

Dr. Walvekar: With a university, you get upfront financial support, though the process is slower. If you’re passionate about your idea early in your career, seek employment with a university with a well-developed innovation center, or connections to hospitals with sophisticated innovation centers.

Dr. Chandrasekhar: Industry feels there is a “cachet” to having academics on their panels, but to me, a panel is incomplete without private practice/community surgeons. There may be more freedom of association outside of academics.

Q: What should a physician know before initiating an ongoing collaboration with industry?

Dr. Suurna: Know that as a company grows, it becomes more regulated. There are more compliance aspects. Things become more complex.

Dr. Kontis: You must understand how clinical trials work and have an International Review Board (IRB) available. Some companies will help with their own referral to an independent IRB, if one is not available through your university.

Dr. Jiam: Surgeons should be part of defining the problem, not brought in at validation. Negative results should be published on the same terms as positive ones, per agreement before the study starts. The institutional intellectual property conversation should be held on day one.

Dr. Chandrasekhar: If the agreement says that the company forever owns any idea you proffer, that is a red flag. If they want to use your name and likeness and you don’t want that, make sure it’s not in the contract. If there is a “noncompete” clause, make sure you’re comfortable with that, because this bleeds into patient care: If you are beholden to one, say, implant company, you may not offer another type with the same energy. If you are starting your own company, look for investors who have not only financial capital, but solid connections and real interest in helping your company succeed over time. Industry will almost always try to low-ball you. Either they’ll offer you a glass of wine or a dinner and then pick your brain, or they’ll offer a much smaller monetary compensation than you deserve. Know your worth! Say you are happy to collaborate and consult, but here’s what it costs.

Dr. Husain: If the relationship being offered isn’t at least equal, or the technology or product doesn’t make sense, or the evidence is weak, walk away. Outside of the walls of medicine, there are products and interventions being developed for our healthcare spaces without rigorous scientific evidence. It is important to speak up about this.

Dr. Walvekar: Even after getting the ideas right, there is developing and commercializing them. There is scaling the idea, which involves people management and capital management, skill sets that physicians are not likely trained to have. That’s why exposing physicians to this kind of thought process early on in their careers could be so valuable.

Q: What are some tips for getting started?

Dr. Husain: Network! Start with your local device rep. They can often connect you with their company’s research and development or marketing division. At meetings or trade events, engage with staff and stop at their booths. Having a LinkedIn profile is also a great way to connect.

Dr. Jiam: Enter a pitch competition. Take an idea to your technology transfer office early, before you have talked about it publicly, and ask about the process. Find the entrepreneurial-minded surgeons on your faculty or look for an I-Corps program. Rigorously write up an unmet need; most physicians do not realize they are sitting on several.

Dr. Suurna: Get to know entrepreneurs, people who have already traveled the path, perhaps set up multiple companies. Then if you have an idea, you can potentially have a mentor or even set up a collaboration.

Dr. Chandrasekhar: Write! Publish! I am not only an avid reader of ENTtoday and Laryngoscope, but I am the consulting editor of Otolaryngologic Clinics of North America. I encourage every guest editor and author to mentor junior people. Their contributions to these review articles, which are indexed, shape them into KOLs: key opinion leaders. When industry is looking for someone to work with, they look for KOLs!

Dr. Rutter: Ask yourself: Would this potentially be useful for my patients? Is it patent-protectable? How big is the market? What would it take to bring it to market? Sometimes you’ll hit a home run and do extremely well, but the primary advice is, don’t go into it for the money; go into it to help your patients.

The ongoing dialogue between otolaryngologists and industry partners is not just about product development; it’s about fostering an ecosystem of continuous improvement. As these collaborations mature, they promise to not only refine existing treatments but also to pioneer entirely new approaches, ultimately benefiting the millions of patients who rely on the expertise and innovation within the field of otolaryngology. The insights shared by these practitioners underscore a collective commitment to pushing the boundaries of medical science, ensuring that the patient remains at the center of every endeavor.